WO2003068803A3 - A nucleic acid encoding a g-protein-coupled receptor, and uses thereof - Google Patents

A nucleic acid encoding a g-protein-coupled receptor, and uses thereof Download PDF

Info

Publication number
WO2003068803A3
WO2003068803A3 PCT/US2003/004350 US0304350W WO03068803A3 WO 2003068803 A3 WO2003068803 A3 WO 2003068803A3 US 0304350 W US0304350 W US 0304350W WO 03068803 A3 WO03068803 A3 WO 03068803A3
Authority
WO
WIPO (PCT)
Prior art keywords
coupled receptor
protein
nucleic acid
acid encoding
receptor
Prior art date
Application number
PCT/US2003/004350
Other languages
French (fr)
Other versions
WO2003068803A2 (en
Inventor
Haifeng Eishingdrelo
Holly Dressler
Jidong Cai
Paul Wright
Original Assignee
Aventis Pharma Inc
Haifeng Eishingdrelo
Holly Dressler
Jidong Cai
Paul Wright
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0219574.1A external-priority patent/GB0219574D0/en
Application filed by Aventis Pharma Inc, Haifeng Eishingdrelo, Holly Dressler, Jidong Cai, Paul Wright filed Critical Aventis Pharma Inc
Priority to JP2003567929A priority Critical patent/JP2005517398A/en
Priority to CA002476239A priority patent/CA2476239A1/en
Priority to BR0307707-1A priority patent/BR0307707A/en
Priority to AU2003213051A priority patent/AU2003213051A1/en
Priority to KR10-2004-7012638A priority patent/KR20040088072A/en
Priority to EP03709093A priority patent/EP1476460A4/en
Priority to MXPA04007006A priority patent/MXPA04007006A/en
Publication of WO2003068803A2 publication Critical patent/WO2003068803A2/en
Publication of WO2003068803A3 publication Critical patent/WO2003068803A3/en
Priority to NO20043582A priority patent/NO20043582L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

Provided herein is a novel and useful G-protein coupled receptor that is involved in signal transduction with respect to inflammation and physiological immunological response. Also provided are methods of using the receptor to screen for molecules that may modulate the activity of the receptor. Such molecules may readily have applications in treating a plethora of inflammation and immunologically related diseases and disorders.
PCT/US2003/004350 2002-02-14 2003-02-13 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof WO2003068803A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2003567929A JP2005517398A (en) 2002-02-14 2003-02-13 Nucleic acid encoding G protein-coupled receptor and use thereof
CA002476239A CA2476239A1 (en) 2002-02-14 2003-02-13 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
BR0307707-1A BR0307707A (en) 2002-02-14 2003-02-13 nucleic acid encoding a g-protein coupled receptor and using it
AU2003213051A AU2003213051A1 (en) 2002-02-14 2003-02-13 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
KR10-2004-7012638A KR20040088072A (en) 2002-02-14 2003-02-13 A nucleic acid encoding a G-protein-coupled receptor, and uses thereof
EP03709093A EP1476460A4 (en) 2002-02-14 2003-02-13 A nucleic acid encoding a g-protein-coupled receptor; and uses thereof
MXPA04007006A MXPA04007006A (en) 2002-02-14 2003-02-13 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof.
NO20043582A NO20043582L (en) 2002-02-14 2004-08-27 A nucleic acid encoding a G protein-coupled receptor and their applications

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35668602P 2002-02-14 2002-02-14
US60/356,686 2002-02-14
GBGB0219574.1A GB0219574D0 (en) 2002-02-14 2002-08-22 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
GB0219574.1 2002-08-22

Publications (2)

Publication Number Publication Date
WO2003068803A2 WO2003068803A2 (en) 2003-08-21
WO2003068803A3 true WO2003068803A3 (en) 2004-07-29

Family

ID=27736226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004350 WO2003068803A2 (en) 2002-02-14 2003-02-13 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof

Country Status (10)

Country Link
EP (1) EP1476460A4 (en)
JP (1) JP2005517398A (en)
CN (1) CN1642971A (en)
AU (1) AU2003213051A1 (en)
BR (1) BR0307707A (en)
CA (1) CA2476239A1 (en)
MX (1) MXPA04007006A (en)
NO (1) NO20043582L (en)
RU (1) RU2004127439A (en)
WO (1) WO2003068803A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
KR101137019B1 (en) * 2009-05-25 2012-05-24 한국생명공학연구원 A novel g protein coupled receptor and a use thereof
CN113588940B (en) * 2021-07-30 2023-05-12 菲鹏生物股份有限公司 Method and kit for improving sensitivity of indirect labeling

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1237909A2 (en) * 1999-11-16 2002-09-11 PHARMACIA & UPJOHN COMPANY Human g protein-coupled receptors
US20040029793A1 (en) * 2000-06-15 2004-02-12 Takeo Moriya Novel g protein-coupled receptor protein and dna thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLAUS LIEBMANN AND FRANK-D. BOEHMER: "Signal transduction pathways of G protein-coupled receptors and thir cross-talk with receptor tyrosine kinases: lessons from bradykinin signalling", CURRENT MEDICINAL CHEMISTRY, vol. 7, 2000, pages 911 - 943, XP002970321 *
DATABASE GENBANK [online] 15 August 2000 (2000-08-15), "Mus musculus chromosome 13 clone RP23-303P5 strain C57BL6/J, WORKING DRAFT SEQUENCE, 18 unordered pieces", XP002974786, Database accession no. AC078995 *
SAUTEL M., MILLIGAN G.: "Molecular manipulation of g-protein-coupled receptors: a new avenue into drug discovery", CURRENT MEDICINAL CHEMISTRY, vol. 7, 2000, pages 889 - 896, XP009001275 *
See also references of EP1476460A4 *

Also Published As

Publication number Publication date
BR0307707A (en) 2005-03-01
MXPA04007006A (en) 2004-10-11
RU2004127439A (en) 2005-04-10
JP2005517398A (en) 2005-06-16
CA2476239A1 (en) 2003-08-21
NO20043582L (en) 2004-08-27
AU2003213051A1 (en) 2003-09-04
WO2003068803A2 (en) 2003-08-21
EP1476460A4 (en) 2005-12-07
CN1642971A (en) 2005-07-20
EP1476460A2 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
EP1170594A3 (en) Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2
AU1679395A (en) Mammalian monocyte chemoattractant protein receptors
HUP0203567A2 (en) April receptor (bcma) and uses thereof
AU1520195A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
CA2220461A1 (en) Therapeutic compounds comprised of anti-fc receptor antibodies
WO2002083866A3 (en) Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
EP2267032A3 (en) Method of administering therapeutic polypeptides, and polypeptides therefor
HK1073653A1 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates and method of preparation
PL398596A1 (en) Preparation containing human antibodies for the treatment of disorders associated with TNF-α
WO2004022718A3 (en) Therapeutic human anti-il-1r1 monoclonal antibody
AU2003281355A1 (en) Modulators of the glucocorticoid receptor
WO2003057837A3 (en) Methods for using anti-muc18 antibodies
ATE450508T1 (en) SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING ABILITY TO HISTAMINE H3 RECEPTORS
WO2001031014A3 (en) G protein-coupled receptors expressed in human brain
WO2003068803A3 (en) A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
EP1736470A3 (en) Pyrimidine derivatives as CB2 cannabinoid receptor modulators
WO2003061365A3 (en) A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
MXPA04004434A (en) A nucleic acid encoding a g-protein-coupled receptor, and uses thereof.
WO2001037874A3 (en) Treatment of psoriasis by using an antibody to tnf alpha
AU2003273995A1 (en) Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
AU2003229716A1 (en) Use of gabab receptor positive modulators in gastro-instestinal disorders
WO2002083736A3 (en) G-protein coupled receptor molecules and uses thereof
WO2004110993A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
BR0313307A (en) Mcp-1 receptor antagonists and method for their use
AU2003259759A1 (en) Gal3 receptor antagonists for the treatment of affective disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/A/2004/007006

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 163355

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1785/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003213051

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2476239

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003567929

Country of ref document: JP

Ref document number: 1020047012638

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003709093

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004127439

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 20038068303

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003709093

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003709093

Country of ref document: EP